KCT0007496
Not yet recruiting
未知
The safety and efficacy of first line palliative chemotherapy and Korean medicine including Rhus verniciflua stokes for patients with unresectable advanced pancreatic cancer or metastatic pancreatic cancer: a prospective observational preliminary study
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Kyung Hee University
- Enrollment
- 30
- Status
- Not yet recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •19 years of age or older
- •Pancreatic cancer (neoplasm) was confirmed by biopsy
- •Who are diagnosed as stage 3 or 4 of TNM staging based on the 8th edition of the AJCC, and are inoperable
- •Who are scheduled for combination treatment with 5\-FU or gemcitabine\-based/mono first palliative chemotherapy and traditional Korean medicine including Rhus verniciflua stokes or within 2 months of starting the treatment
- •Whose life expectancy is more than 3 months
- •The Eastern Cooperative Oncology Group (ECOG) performance status score 0\-2
- •Those who understand the research content and agree to participate in the research
Exclusion Criteria
- •Pregnant women, lactating women
- •Patients with active brain metastases showing clinically significant neurological symptoms or signs
- •Those who have clinically significant skeletal related events, including pathological fractures and spinal cord compressions, and require radiotherapy or surgical therapy
- •Those who have been diagnosed with other new primary cancers that may affect the patient's condition within the last 5 years
- •Who are judged to be inappropriate for the research
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Efficacy and safety of first-line therapy with chlorambucil, rituximab and lenalidomide (Revlimid®) (CR2) in elderly patients and young frail patients with advanced Chronic Lymphocytic Leukemia (CLL): a phase II trialChronic Lymphatic LeukemiaCLL10024324NL-OMON36713HOVO62
Completed
Phase 2
Efficacy and feasibility of first-line treatment with risk-adapted dose-adjusted EPOCH-R (DA-EPOCH-R) in patients with Burkitt lymphoma. A phase II clinical trial.Burkitt lymphomahighly aggressive B cell lymphoma10025320NL-OMON36941Vrije Universiteit Medisch Centrum22
Active, not recruiting
Not Applicable
A trial to investigate treatment with EPOCH-R in patients with Burkitt lymphoma, by adapting the dose to the risk classification of the disease.Burkitt lymphomaMedDRA version: 14.1Level: HLTClassification code 10006596Term: Burkitt's lymphomasSystem Organ Class: 10005329 - Blood and lymphatic system disordersTherapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2012-003141-16-NLVU University Medical Center
Completed
Phase 4
Efficacy and safety of the medications of first line treatment (artesunate+amodiaquine) and second line treatment (artemether+lumefantrine) for the treatment of uncomplicated Plasmodium falciparum in Malabo, Bata and Ebibey, Equatorial GuineeACTRN12617000456358Ministry of Public Health of Equatorial Guinea528
Completed
Not Applicable
A randomised phase 3 trial of Palliative care Early in Advanced Lung Cancers.Adults with advanced thoracic malignancy (NSCLC, SCLC orMPM) that have been newly diagnosed within the last 60 days.Adults with advanced thoracic malignancy (NSCLC, SCLC orMPM) that have been newly diagnosed within the last 60 days.Cancer - Lung - Small cellCancer - Lung - Non small cellCancer - Lung - MesotheliomaACTRN12617000166370niversity of Sydney113